Dear colleagues,
With GAVI's recent announcement incorporating the category of TPVS active vaccine carriers into the Cold Chain Equipment Optimization Platform (CCEOP), I wanted to open up a discussion to gather your inputs and suggestions on this development.
As immunization professionals, we are aware of the critical role cold chain equipment plays in ensuring vaccine potency and delivery. The inclusion of TPVS active carriers in CCEOP raises several interesting considerations:
-
Relevance and Use Cases:
- How relevant are TPVS active vaccine carriers in your operational context?
- Do you see them addressing specific gaps that current equipment may not fully meet?
-
Performance and Practicality:
- What are your thoughts on the reliability and practicality of these devices in field conditions, especially in hard-to-reach areas?
- Are there challenges in integrating TPVS technology into your existing workflows?
-
Impact of CCEOP Inclusion:
- What could this inclusion mean for funding, accessibility, and adoption of these devices?
- Are there any particular considerations or support mechanisms you'd expect to ensure successful implementation?
Your insights will be invaluable in shaping how we collectively understand and utilize this category of equipment. Please feel free to share your experiences, concerns, or questions related to TPVS carriers.
Looking forward to a robust and insightful discussion!
Thank you for initiating this important discussion.
The inclusion of TPVS active vaccine carriers in CCEOP is a positive development, particularly for immunization programs operating in challenging environments where maintaining temperature throughout transport remains a significant concern.
From my perspective, these devices could help address gaps in last-mile vaccine delivery, outreach sessions, and prolonged transport to remote or hard-to-reach communities where passive cold boxes may not always provide sufficient temperature assurance. Their ability to actively maintain the required temperature range has the potential to reduce vaccine wastage and improve confidence in vaccine potency.
That said, successful adoption will depend on more than the technology itself. Considerations such as total cost of ownership, maintenance requirements, battery performance and charging infrastructure, availability of spare parts, local technical support, and user training will be critical to long-term sustainability. Programs will also need clear guidance on selecting appropriate use cases where the added value of TPVS carriers justifies the investment.
The inclusion under CCEOP could significantly improve access by enabling countries to evaluate and procure these devices through established funding mechanisms. However, implementation should be accompanied by operational guidance, performance monitoring, and documentation of country experiences to build the evidence base for broader adoption.
Overall, I see TPVS active carriers as a valuable addition to the cold chain toolkit—not a replacement for existing passive equipment, but a complementary solution for specific operational scenarios where they offer clear advantages.
- Page :
- 1